First-Line Treatment Decisions in Metastatic Pancreatic Cancer: Setting the Stage

The first-line treatment landscape for metastatic pancreatic ductal adenocarcinoma (mPDAC) has evolved significantly, yet options remain limited for this challenging disease. This opening segment explores how performance status, age, frailty, molecular profiling, and patient preferences drive treatment selection. The conversation examines key distinctions between triplet regimens including modified FOLFIRINOX and NALIRIFOX and doublet therapy, comparing toxicity profiles including myelosuppression, neuropathy, and GI side effects. The recent FDA approval has expanded physician flexibility and enabled more individualized treatment decisions. Critically, the discussion underscores the importance of front-line regimen selection given high attrition rates, with only approximately 50% of patients reaching second-line therapy, making the initial treatment choice a pivotal determinant of long-term disease management strategy and a decision that must carefully balance efficacy, tolerability, and the patient's own goals of care.